CN1902186B - 作为flt-3激酶抑制剂的噻唑和吡唑衍生物 - Google Patents
作为flt-3激酶抑制剂的噻唑和吡唑衍生物 Download PDFInfo
- Publication number
- CN1902186B CN1902186B CN2004800403740A CN200480040374A CN1902186B CN 1902186 B CN1902186 B CN 1902186B CN 2004800403740 A CN2004800403740 A CN 2004800403740A CN 200480040374 A CN200480040374 A CN 200480040374A CN 1902186 B CN1902186 B CN 1902186B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- compound
- formula
- group
- title compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0326601.2A GB0326601D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
GB0326601.2 | 2003-11-14 | ||
PCT/EP2004/012892 WO2005047273A1 (fr) | 2003-11-14 | 2004-11-12 | Derives de thiazole et de pyrazole en tant qu'inhibiteurs de la kinase flt-3 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1902186A CN1902186A (zh) | 2007-01-24 |
CN1902186B true CN1902186B (zh) | 2010-12-22 |
Family
ID=29726576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800403740A Expired - Fee Related CN1902186B (zh) | 2003-11-14 | 2004-11-12 | 作为flt-3激酶抑制剂的噻唑和吡唑衍生物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7795288B2 (fr) |
EP (1) | EP1687285B1 (fr) |
JP (1) | JP4869939B2 (fr) |
KR (1) | KR20060108673A (fr) |
CN (1) | CN1902186B (fr) |
AU (2) | AU2004289447A1 (fr) |
BR (1) | BRPI0416039A (fr) |
CA (1) | CA2545350A1 (fr) |
ES (1) | ES2469644T3 (fr) |
GB (1) | GB0326601D0 (fr) |
MX (1) | MXPA06005356A (fr) |
RU (1) | RU2006120490A (fr) |
WO (1) | WO2005047273A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005287170B2 (en) | 2004-09-17 | 2012-03-29 | Exelixis, Inc | Pyrazole kinase modulators and methods of use |
MX2007012392A (es) * | 2005-04-04 | 2007-12-05 | Ab Science | Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa. |
ZA200710105B (en) * | 2005-05-24 | 2009-04-29 | Serono Lab | Thiazole derivatives and use thereof |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US20060281769A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281700A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
US20060281755A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
KR20080031997A (ko) * | 2005-08-02 | 2008-04-11 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 5-치환 티아졸-2-일 아미노화합물 및 조성물 |
CN101610768B (zh) * | 2006-04-20 | 2012-03-21 | 詹森药业有限公司 | 抑制c kit激酶的方法 |
US8859602B2 (en) | 2006-04-20 | 2014-10-14 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
PL2021335T3 (pl) | 2006-04-20 | 2011-10-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory kinazy C-FMS |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US8993615B2 (en) | 2008-08-08 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2011119777A2 (fr) | 2010-03-23 | 2011-09-29 | The Johns Hopkins University | Compositions et méthodes de traitement d'une maladie neurodégénérative |
US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
US9303046B2 (en) | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CN104829536B (zh) * | 2015-05-04 | 2017-12-29 | 陕西科技大学 | 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法 |
CN108690006B (zh) * | 2017-04-12 | 2022-02-18 | 中国药科大学 | 一类化合物及其在抗aml药物中的用途 |
CN110732500B (zh) * | 2018-07-19 | 2024-02-27 | 湖南农业大学 | 一种基于机器视觉的芒果分级装置 |
CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062215A1 (fr) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649146A (en) * | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
EP0149884B1 (fr) * | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | Dérivés de 5-pyridyle-1,3-thiazole, leur préparation et utilisation |
GB8611102D0 (en) * | 1986-05-07 | 1986-06-11 | Fisons Plc | Heterocyclic compounds |
EP0248523B1 (fr) * | 1986-05-07 | 1991-10-16 | FISONS plc | Pyrazoles |
JPH11193281A (ja) * | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンa3受容体拮抗剤およびチアゾール化合物 |
BR9915132A (pt) * | 1998-11-06 | 2001-08-07 | Basf Ag | Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica. |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
JP2002531503A (ja) * | 1998-12-07 | 2002-09-24 | スミスクライン・ビーチャム・コーポレイション | Myt1キナーゼ阻害剤 |
HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
BRPI0412820A (pt) * | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
-
2003
- 2003-11-14 GB GBGB0326601.2A patent/GB0326601D0/en not_active Ceased
-
2004
- 2004-11-12 ES ES04818403.0T patent/ES2469644T3/es active Active
- 2004-11-12 BR BRPI0416039-8A patent/BRPI0416039A/pt not_active IP Right Cessation
- 2004-11-12 RU RU2006120490/04A patent/RU2006120490A/ru not_active Application Discontinuation
- 2004-11-12 MX MXPA06005356A patent/MXPA06005356A/es unknown
- 2004-11-12 KR KR1020067009281A patent/KR20060108673A/ko not_active Application Discontinuation
- 2004-11-12 JP JP2006538814A patent/JP4869939B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP04818403.0A patent/EP1687285B1/fr not_active Not-in-force
- 2004-11-12 WO PCT/EP2004/012892 patent/WO2005047273A1/fr active Application Filing
- 2004-11-12 AU AU2004289447A patent/AU2004289447A1/en not_active Abandoned
- 2004-11-12 CA CA002545350A patent/CA2545350A1/fr not_active Abandoned
- 2004-11-12 US US10/578,826 patent/US7795288B2/en not_active Expired - Fee Related
- 2004-11-12 CN CN2004800403740A patent/CN1902186B/zh not_active Expired - Fee Related
-
2009
- 2009-06-29 AU AU2009202639A patent/AU2009202639A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003062215A1 (fr) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
Non-Patent Citations (1)
Title |
---|
synthesis and properties of2-amino-5-(3,5,6-trichloro)-1,4-benzoquinon-2-yl)thiazoles.khimiya geterotsiklicheskikh soedinenii5.1988,5692-698. * |
Also Published As
Publication number | Publication date |
---|---|
CN1902186A (zh) | 2007-01-24 |
EP1687285A1 (fr) | 2006-08-09 |
EP1687285B1 (fr) | 2014-03-05 |
AU2004289447A1 (en) | 2005-05-26 |
GB0326601D0 (en) | 2003-12-17 |
JP2007511484A (ja) | 2007-05-10 |
BRPI0416039A (pt) | 2007-01-02 |
JP4869939B2 (ja) | 2012-02-08 |
WO2005047273A1 (fr) | 2005-05-26 |
RU2006120490A (ru) | 2008-01-10 |
AU2009202639A8 (en) | 2009-07-30 |
AU2009202639A1 (en) | 2009-07-23 |
CA2545350A1 (fr) | 2005-05-26 |
MXPA06005356A (es) | 2006-07-10 |
KR20060108673A (ko) | 2006-10-18 |
US7795288B2 (en) | 2010-09-14 |
US20070167449A1 (en) | 2007-07-19 |
ES2469644T3 (es) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1902186B (zh) | 作为flt-3激酶抑制剂的噻唑和吡唑衍生物 | |
JP4667463B2 (ja) | チロシンキナーゼ阻害剤として適する環状ジアリールウレア | |
US7390805B2 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
JP6453845B2 (ja) | Brd4阻害薬としてのジヒドロキナゾリノン類似体 | |
CN1882578B (zh) | 作为zap-70和/或syk抑制剂的2,4-二(杂)芳基氨基嘧啶衍生物 | |
CA2646952C (fr) | Derives de pyrrole, de thiophene et de furane substitues par un pyridyle et derives de pyrrole, de thiophene et de furane substitues par un pyrimidinyle en tant qu'inhibiteurs de kinase | |
JP5871896B2 (ja) | B−rafキナーゼインヒビター | |
JP2003509342A (ja) | チロシンキナーゼ阻害薬 | |
EP1940846B9 (fr) | Composés de pyrimidin-4-yl-3,4-dihydro-2h-pyrrolo[1,2a]pyrazin-1-one | |
MX2007008373A (es) | Derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina y su uso en terapia. | |
AU2008279776A1 (en) | Heterocyclic amide compounds as protein kinase inhibitors | |
MXPA01011441A (es) | Derivados de 4,5,6,7-tetrahidroindazol como agentes antitumorales. | |
JP2009539840A (ja) | プロテインキナーゼ阻害剤としてのイミダゾピラジン | |
MXPA06003054A (es) | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. | |
AU2005205118A1 (en) | Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors | |
KR102445744B1 (ko) | Smac 모방체로서의 6-알키닐 피리딘 유도체 | |
TW201300396A (zh) | 化合物及其用於治療與Aβ相關疾病之用途 | |
CN101010300A (zh) | 2-苯基吡啶衍生物 | |
US7323469B2 (en) | 7H-pyrrolo[2,3-d]pyrimidine derivatives | |
CN104995183B (zh) | 新的磷酸二酯酶10a型的抑制剂化合物 | |
CA3227194A1 (fr) | Composes pour le traitement de la douleur, en particulier de la douleur neuropathique, et/ou d'autres maladies ou troubles associes a at2r et/ou a la signalisation mediee par at2r | |
OA20638A (en) | Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer. | |
KR20070094949A (ko) | 2-(시클릭 아미노카르보닐)인돌린 유도체 및 그것을함유하는 약제학적 조성물 | |
KR20030064077A (ko) | 새로운 3-하이드록시크로멘-4-온 구조를 갖는 사이클린의존 키나아제 저해제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101222 Termination date: 20151112 |